foxo4-dri senolytic peptide human trial The disordered p53 transactivation domain
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications Peptide inhibitors targeting FOXO4 p53 interactions and inducing senescent cancer cell specific apoptosis bioRxiv Buy FOXO4 DRI Exceptional 99%+ Purity Third Party COA Included Buy FOXO4 DRI UK 98% Purity Next Day Dispatch
Pay in 4 interest-free payments of $6.38 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18



